The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

$ 26.50

4.5
(740)
In stock
Description

C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition - ScienceDirect

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

NCT-58 - ZellBio GmbH

Recent advances toward the development of Hsp90 C-terminal inhibitors - ScienceDirect

Biomolecules, Free Full-Text

Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances - ScienceDirect

Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer

Cancers, Free Full-Text

Soeun Park's research works Korea University, Seoul (KU) and other places

Cancers, Free Full-Text

A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

Detailed curriculum vitae of HER2-targeted therapy - ScienceDirect

Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation